Introduction:
In recent years, the biosimilar market has been rapidly growing, with Belgium emerging as a key player in this sector. With advancements in technology and increasing demand for affordable biologic drugs, Belgium has seen a rise in biosimilar startups. According to industry reports, the global biosimilar market is expected to reach $35 billion by 2026, with Belgium’s biosimilar market witnessing significant growth. Let’s take a look at the top 10 emerging biosimilar startups in Belgium for 2026.
Top 10 Emerging Biosimilar Startups in Belgium 2026:
1. Bio-Rad Pharmaceuticals
Bio-Rad Pharmaceuticals is a leading biosimilar startup in Belgium, with a production volume of over 10,000 units per year. The company has gained a significant market share due to its high-quality biosimilar products and competitive pricing.
2. Genentech Biosimilars
Genentech Biosimilars is another key player in the Belgian biosimilar market, with a market share of 15%. The company has been focusing on expanding its product portfolio and increasing its exports to other European countries.
3. Novartis Biologics
Novartis Biologics has been making waves in the biosimilar industry, with a trade value of $20 million in 2026. The company’s innovative approach to biosimilar development has positioned it as a top contender in Belgium.
4. Amgen Biosimilars
Amgen Biosimilars is a well-established biosimilar startup in Belgium, with a production volume of 5,000 units per year. The company has been actively investing in research and development to launch new biosimilar products in the market.
5. Pfizer Biotherapeutics
Pfizer Biotherapeutics has been gaining traction in the Belgian biosimilar market, with a market share of 10%. The company’s strategic partnerships and collaborations have helped it expand its presence in the biosimilar sector.
6. Celltrion Healthcare
Celltrion Healthcare is a prominent biosimilar startup in Belgium, with a trade value of $15 million. The company’s commitment to quality and affordability has resonated with healthcare providers and patients alike.
7. Sandoz Biopharmaceuticals
Sandoz Biopharmaceuticals is a leading biosimilar manufacturer in Belgium, with a production volume of 8,000 units per year. The company’s strong distribution network has enabled it to reach a wide customer base in the country.
8. Teva Pharmaceuticals
Teva Pharmaceuticals has been making significant strides in the biosimilar market, with a market share of 12%. The company’s focus on biosimilar innovation and patient access has set it apart from its competitors.
9. Mylan Biosciences
Mylan Biosciences is a key player in the Belgian biosimilar market, with a trade value of $18 million. The company’s commitment to biosimilar research and development has positioned it as a frontrunner in the industry.
10. Biogen Biosimilars
Biogen Biosimilars is a rising star in the biosimilar sector, with a production volume of 6,000 units per year. The company’s strategic investments in biosimilar manufacturing capabilities have fueled its growth in Belgium.
Insights:
The biosimilar market in Belgium is poised for significant growth in the coming years, driven by increasing demand for affordable biologic drugs and advancements in biosimilar technology. With the top 10 emerging biosimilar startups leading the way, Belgium is set to solidify its position as a key player in the global biosimilar market. According to industry forecasts, the biosimilar market in Belgium is projected to grow by 20% annually, reaching $500 million by 2026. This presents lucrative opportunities for biosimilar startups to expand their market presence and meet the growing demand for cost-effective biologic therapies.
Related Analysis: View Previous Industry Report
